Under Turkish law, only entities registered in Türkiye are eligible to obtain a marketing authorization (“MA”) for medicinal products for human use. This requirement compels global pharmaceutical companies intending to engage in business in Türkiye to establish local presence either through forming a subsidiary or teaming up with a local partner such as a distributor. In case of a partnership (e.g., established through a distributorship relationship), transfer of MA will be one of the main topics to be discussed if and when such partnership comes to an end. This article provides an overview of the regulatory framework governing the transfer of MAs in Türkiye, with a particular focus on transfers where there may potentially be a disagreement between the transferor and the transferee.
According to the Regulation on the Licensing of Medicinal Products for Human Use (“Regulation”) and the Guidelines on Conditions Requiring Re-authorisation for Licensed Medicinal Products for Human Use, in order to transfer an MA, certain documents must be submitted to the Turkish Medicine and Medical Device Agency (“TMMDA”), and the relevant procedures must be completed. Transfer process has two main aspects: (i) submission of the transfer application to the TMMDA and (ii) cooperation of the transferor.
In the application for the transfer, the transferee must submit to the TMMDA: (i) a court decision stating that the transfer of MA has been fulfilled, (ii) an execution office decision stating that the license has been sold through forced execution proceedings, or (iii) a transfer agreement executed between the transferee and the transferor before a notary public.
Upon submission of the required documentation and payment of the application fees, the review process will commence where the TMMDA shall look into the application to confirm that all regulatory requirements are met, with a particular focus on whether the transferee is well equipped to manage the respective medicinal product in a responsible manner. The TMMDA shall make an assessment on the application within thirty days of the application date, and can request further information or documents, which would re-start the review period. Once the review process is completed, approval will be granted and the MA registry will be updated to reflect the change in the ownership, and the new holder will assume all rights and responsibilities associated with the authorisation.
Share
Related persons
You can contact us for detailed information.


Legal Information
This briefing is for information purposes; it is not legal advice. If you have questions, please call us. All rights reserved.
You May Be Interested In
7 October 2025
Turkish Data Protection Authority eases registration requirements for organisations processing sensitive data
In Decision No. 2025/1572 dated 4 September 2025, the Turkish Data Protection Authority introduced an exemption for data controllers…
6 October 2025
New Communiqué on the Right of Access to the File has been Published
With the Communiqué Amending the Communiqué (Communiqué No: 2010/3) on the Regulation of the Right of Access to the File and Protection of…
3 September 2025
A Milestone for Eurasian Connectivity: The Middle Corridor’s Strategic Emergence and Türkiye’s Geopolitical Role
The launch of the first direct freight train service from China to Europe via the Trans-Caspian International Transport Route (TITR),…
28 July 2025
Recent Changes in Mining, Renewable Energy and Electricity Legislation
Law No. 7554 on Amendments to Certain Laws, which introduces changes to many fundamental pieces of legislation applicable to the energy…
25 July 2025
The United Kingdom Sanctions: Risks and Roadmap for Turkish Companies
On June 27, 2025, the UK Foreign, Commonwealth and Development Office (“FCDO“) published Sanctions Guidance for Non-UK Businesses…
21 July 2025
Recent Developments in Healthcare Legislation – Q2 2025
Amendment to the Regulation on the Clinical Trials of Medicinal Products for Human Use. On 5 June 2025, the Regulation on Clinical Trials…